Femasys Announces FDA Approval of Modular PMA Pathway for FemBloc Non-Surgical Permanent Birth Control
核心洞察
The U.S. FDA has approved Femasys' modular premarket approval application (PMA) pathway for FemBloc (搜索), its investigational non-surgical permanent birth control technology.
The modular approach allows key submission components to be reviewed by the FDA in advance of final clinical data, enabling meaningful regulatory progress.
FemBloc (搜索) is a first-of-its-kind, in-office solution requiring no anesthesia, incisions, or recovery time, addressing a significant unmet need in women's reproductive health.
Femasys Inc. (NASDAQ: FEMY), a biomedical innovator developing fertility and non-surgical permanent birth control solutions, announced that the U.S. Food and Drug Administration has approved the Company's modular premarket approval application (PMA) pathway for FemBloc (搜索), its investigational non-surgical permanent birth control technology in the United States. FemBloc is already approved for marketing in Europe and other select international markets.
"FDA approval of the modular PMA pathway provides a clear and efficient framework for advancing FemBloc (搜索) toward U.S. approval, allowing key components of the submission to be reviewed by FDA in advance of the final clinical data," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. "This approach enables us to make meaningful regulatory progress as the clinical program advances."
A First-of-Its-Kind Non-Surgical Approach
FemBloc (搜索) is described as a first-of-its-kind solution for permanent birth control designed to be delivered in the OB/GYN office, addressing a significant unmet need in women's reproductive health. The technology combines a patented delivery system with a separately patented blended polymer that is placed into both fallopian tubes, safely degrades, and forms natural scar tissue for permanent occlusion.
Unlike surgical sterilization, FemBloc (搜索) requires no anesthesia, incisions, or recovery time, offering women a more convenient and affordable alternative while avoiding risks associated with surgery.
Regulatory and Commercial Strategy
Lee-Sepsick noted that, in parallel with the regulatory pathway, Femasys is building a U.S. commercial team as it broadens commercialization of its fertility portfolio beyond infertility specialists to OB/GYNs, helping bring fertility care earlier in the patient journey. "This same team is intended to ultimately support FemBloc (搜索), creating an efficient commercial foundation for expanding access to transformative reproductive health technologies through the OB/GYN setting," she said.
Femasys is advancing FemBloc (搜索) toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK, and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets.
Company Portfolio and Clinical Data
Femasys is focused on commercializing its fertility portfolio, led by FemaSeed (搜索) Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. The Company's portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.